Risk Factors Update Summary
- BDTX - 4933 now being evaluated in a Phase 1 clinical trial, previously planned for the first half of 2023.
- Accumulated deficit increased from $335 million to $417 million from 2022 to 2023.
- Net losses decreased from $91.2 million to $82.4 million from 2022 to 2023.
- Number of full-time employees decreased from 65 to 52 from 2022 to 2023.
- Gross U.S. federal net operating loss carryforwards decreased from $241 million to $182 million from 2022 to 2023.
- Net proceeds from the initial public offering are expected to fund operations into the second quarter of 2025.
- Fast Track Designation received for BDTX - 1535 for metastatic EGFRm C797S-positive NSCLC.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1701541&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.